InflaRx N.V. (IFRX) to Offer Common Stocks and Warrants

InflaRx N.V. (Nasdaq: IFRX) announced today that it has commenced an underwritten public offering of common shares of the Company. For each common share purchased, an investor will also receive a warrant to purchase a common share of the Company. The Company intends to use the net proceeds from the offering primarily to fund research and development expenses for its clinical and preclinical research and development activities and for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Guggenheim Securities, LLC and Raymond James & Associates, Inc. are serving as joint book-running managers for the proposed offering.

You May Also Be Interested In

• Amylyx Pharmaceuticals launches $350M common stock offering
• Raymond James Downgrades Accelerant Holdings (ARX) to Market Perform
• Praxis Precision Medicines Inc. (PRAX) PT Raised to $945 at Raymond James